Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials

INTRODUCTION: Galcanezumab, a humanized monoclonal antibody that binds to calcitonin gene-related peptide, is approved for the preventive treatment of migraine in adults. It is self-administered once monthly as a subcutaneous injection. This paper describes the time course of effect of galcanezumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuruppu, Dulanji K., North, James M., Kovacik, Amy J., Dong, Yan, Pearlman, Eric M., Hutchinson, Susan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932975/
https://www.ncbi.nlm.nih.gov/pubmed/33544305
http://dx.doi.org/10.1007/s12325-021-01632-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7932975/
https://www.ncbi.nlm.nih.gov/pubmed/33544305
http://dx.doi.org/10.1007/s12325-021-01632-x

Ejemplares similares